Answer
It has licences across several solid tumours and classical Hodgkin lymphoma. The exact use depends on cancer type, stage, previous treatment, biomarker results and whether it is being used alone or in combination.
Sources for this answer
- KEYTRUDA 25 mg/mL concentrate for solution for infusion — Current selected SmPCemc · Summary of Product Characteristics
- KEYTRUDA 395 mg solution for injection — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.